Founded in 1994, Amanta Healthcare operates as a specialized pharmaceutical manufacturing company focused on sterile liquid formulations. The organization serves diverse therapeutic areas including fluid therapy solutions, respiratory medications, ophthalmic products, medical diluents, and irrigation formulations.
Amanta Healthcare IPO
Pharmaceutical Formulation Manufacturer
LIVE IPO₹14,994 (Retail)
Event | Date |
---|---|
Issue Open Date | 01 Sep 2025 |
Issue Close Date | 03 Sep 2025 |
UPI Mandate Deadline | 03 Sep 2025 (5 PM) |
Allotment Finalization | 04 Sep 2025 |
Refund Initiation | 08 Sep 2025 |
Share Credit | 08 Sep 2025 |
Listing Date | 09 Sep 2025 |
Mandate End Date | 18 Sep 2025 |
Founded in 1994, Amanta Healthcare operates as a specialized pharmaceutical manufacturing company focused on sterile liquid formulations. The organization serves diverse therapeutic areas including fluid therapy solutions, respiratory medications, ophthalmic products, medical diluents, and irrigation formulations.
The company’s production facility spans over 66,000 square meters in Hariyala, Kheda district, Gujarat. This state-of-the-art manufacturing unit features advanced LVP (Large Volume Parenteral) and SVP (Small Volume Parenteral) production lines utilizing ABFS (Aseptic Blow Fill Seal) and ISBM (Injection Stretch Blow Molding) technologies. The facility maintains WHO-GMP compliance and has earned multiple quality certifications including ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, and ISO 45001:2018.
Issue Size Breakdown
Fund Utilization
- Nearly three decades of operational experience since 1994 with a broad pharmaceutical product range
- Sophisticated sterile liquid production capabilities spanning various volume specifications
- Quality-assured manufacturing facility with international certifications and cutting-edge technology
- Well-established distribution channels covering both domestic and international markets
- Strong management team supported by a competent and qualified workforce
- Significant reliance on key customers creates potential revenue volatility and business dependency concerns
- Potential delays in SteriPort and SVP facility expansion could hinder projected growth objectives
- Personal guarantees by promoters on company loans may create operational constraints
- Manufacturing sterile liquid pharmaceuticals involves substantial product liability risks
- Dependence on unsecured loans and personal guarantees may increase overall financial risk exposure
Application statistics recorded at 5:00 PM on September 01, 2025:
Category | Reserved (Lakhs) | Applied (Lakhs) | Subscription |
---|---|---|---|
Institutional | 20.00 | 0.78 | 0.04x |
NII | 15.00 | 87.33 | 5.82x |
Retail | 35.00 | 235.04 | 6.72x |
Total | 70.00 | 323.16 | 4.62x |